BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

TeraDiscoveries Announces the Design of Six New Drugs In-Silico as Part of Strategic Relationship


6/15/2012 9:51:44 AM

RESEARCH TRIANGLE PARK, N.C., June 14, 2012 /PRNewswire/ -- TeraDiscoveries, Inc., announced today the identification of the first six biological targets for which the company is designing new drug candidates. This development follows the formation of a strategic relationship TeraDiscoveries has established with Microsoft Corp. Microsoft is providing support and cloud computing time on Windows Azure that TeraDiscoveries is applying to identify inhibitors of 25 top biological targets. The first six targets, which are now undergoing computer modeling, are HDAC8, JAK3, JAK2, PGP, HSP90, and the thioredoxin/glutathione reductase protein from the Schistosoma parasite.

"We are developing a JAK3 kinase inhibitor that is selective against JAK1 and JAK2 enzymes and is indicated for rheumatoid arthritis treatment. We are also developing inhibitors for proteins with oncology indications, all of which are screened by sophisticated software for potential toxicology problems," says Ed Addison, CEO of TeraDiscoveries.

One of TeraDiscoveries top inhibitors is for the thioredoxin/glutathione reductase protein associated with Schistosomiasis, also known as bilharzias. This is an orphan disease caused by parasitic worms that currently affects over 200 million people worldwide, mostly in developing countries. The newly described X-ray structure of the Schistosoma ssp. parasite will allow the design of much needed small molecule inhibitors to combat this disease.

TeraDiscoveries uses its Inverse Design software that runs computational models to quickly scan virtual chemical libraries to find the strongest inhibitors of a specific biological target. The process identifies novel drug candidates that feature good clinical trial properties and demonstrate low probability of toxic side effects. Designing new drugs that bind to a specified protein target requires finding the best molecule in a vast chemical space. TeraDiscoveries' approach searches this space much more efficiently and cost-effectively than traditional methods.

Companies can license molecules designed by TeraDiscoveries, or they can contract for services using Inverse Design running on Windows Azure to design, discover, or optimize new small molecule or peptide drugs for their targets. TeraDiscoveries also provides drug discovery and preclinical development services for companies seeking outside assistance.

TeraDiscoveries will be presenting Inverse Design in the North Carolina Pavilion (booth 2935) at the 2012 BIO International Convention taking place June 18 to 21, 2012, in Boston. CEO Ed Addison will be delivering a 30-minute presentation on Inverse Design in the pavilion on Wednesday, June 20 at 2:30pm.

About TeraDiscoveries, Inc.

TeraDiscoveries is a drug discovery company located in Research Triangle Park, North Carolina. The company's Inverse Design software enables a paradigm shift to dramatically accelerate traditional drug discovery, simultaneously resulting in completely novel molecules. This proprietary software combined with cloud computing enables the rapid and accurate discovery of novel drug candidates to serve as a catalyst for improved health and well-being. Visit www.teradiscoveries.com for information.

All product and company names herein may be trademarks of their respective owners.

SOURCE TeraDiscoveries, Inc.



Read at BioSpace.com

 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES